Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Attenuated streptococcus suis vaccines and methods of making and use thereof

A technology of Streptococcus suis and strains, applied in the direction of vaccines, veterinary vaccines, bacteria, etc., can solve the problem of lack of effective vaccines

Active Publication Date: 2015-07-15
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Lack of an effective vaccine against S. suis infection is a major problem in modern pig production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Attenuated streptococcus suis vaccines and methods of making and use thereof
  • Attenuated streptococcus suis vaccines and methods of making and use thereof
  • Attenuated streptococcus suis vaccines and methods of making and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1 - Generation and genome analysis of attenuated S. suis

[0111] To develop a vaccine with broad protection against S. suis infection, the US field strain (parental strain, Newport Laboratory No. 8-1433-1, SEQ ID NO: 9) was isolated from pig brain cotton swabs. Based on biochemical reactions and agglutination tests, the isolate was identified as S. suis serotype 2. Attenuation of this parental strain was accomplished by chemical mutagenesis using acriflavine hydrochloride as described by Sinha et al. Briefly, S. suis parental cells were incubated for 18 hours in tryptic casein soybean broth supplemented with 10 [mu]M / ml acriflavine hydrochloride containing 5% sheep blood. Surviving cells were reisolated on sheep blood agar plates. 20 single colonies were selected and grown separately in the same liquid medium. One of these 20 cultures was selected and injected (1.76 × 10 9 cells / ml) into pigs to determine virulence. Ten pigs were inoculated orally and obse...

Embodiment 2

[0120] Example 2 - Efficacy of attenuated S. suis vaccine in pigs

[0121] General protocol for efficacy studies: Colony forming units (CFU) / ml were determined for each vaccine dilution throughout the titration period before and after vaccination.

[0122] All pigs enrolled in these studies were obtained from Midwest Research Swine, Gibbon, MN and were healthy and normal upon arrival. The herd was considered to be a highly healthy source herd with no history of S. suis infection and negative for porcine reproductive and respiratory syndrome virus (PRRSV). The source herd piglets had a history of susceptibility to S. suis challenge in previous studies. Pigs are received at 17-24 days of age. Animals were observed prior to inoculation and were considered clinically normal because they lacked signs of disease, including coughing, abdominal respiration, and / or lameness. Individual pigs were used as experimental units in these studies and ear-tagged prior to arrival. Pigs were ra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides attenuated S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations in S. suis genes, which are useful in the production of novel attenuated S. suis bacterial strains.

Description

[0001] incorporated by reference [0002] This application claims priority to provisional application USSN 61 / 664,935, filed June 27, 2012 and incorporated herein by reference in its entirety. technical field [0003] The present invention relates generally to attenuated bacterial vaccines, especially those that provide broad, safe and effective protection to pigs from infection / disease caused by Streptococcus suis. The invention also relates to methods of producing attenuated bacteria and to identifying nucleic acid variations associated with reduced virulence of the attenuated bacteria. [0004] The present invention thus relates to immunogenic or vaccine compositions comprising bacteria of the invention (eg, live attenuated bacteria). The bacteria may also be inactivated in the composition; however it may be advantageous if the bacteria are live attenuated S. suis bacteria. Accordingly, the invention also relates to methods for preparing and / or formulating such compositio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/09
CPCA61K2039/552A61K2039/522A61K2039/542A61K39/092A61P11/00A61P19/02A61P31/04A61P37/04A61K39/09C12N1/20
Inventor R·F·贝P·K·劳伦斯R·R·西蒙森K·R·西里吉雷迪D·A·麦基翁
Owner BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products